Articles tagged "Lung transplantation"

2021 American Transplant Congress
A Randomized, Multicenter, Blinded Study Assessing the Effects of Gaseous Nitric Oxide in an Ex Vivo System of Human Lungs
M. G. Hartwig¹, J. A. Klapper¹, N. Poola², A. Banga³, P. G. Sanchez⁴, J. S. Murala³, J. L. Potenziano²
¹Duke University Medical Center, Durham, NC, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: The effects of nitric oxide (NO) on donor lungs during ex vivo lung perfusion (EVLP) have not been studied. We assessed whether the novel…
2021 American Transplant Congress
Alpha 1-antitrypsin Reduces Cytokine Elaboration in a Xenogeneic Lung Transplantation Model
L. Burdorf¹, C. Laird², T. Zhang², M. R. Connolly¹, Z. Habibabady¹, S. Pratts¹, S. Miura¹, F. Pollok¹, W. Eyestone³, C. J. Phelps³, D. L. Ayares³, A. M. Azimzadeh¹, R. N. Pierson III¹
¹Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Surgery, University of Maryland, Baltimore, MD, ³Revivicor, Blacksburg, VA
*Purpose: Novel gene editing techniques have facilitated the generation of donor pigs with multiple genetic modifications, used for xenolung transplantation. Several rejection pathways, including antibody…
2021 American Transplant Congress
A Case-Match Cohort Comparison of the Safety and Efficacy of Basiliximab for Immunosuppression Holiday in Lung Transplant Patients
M. M. Eiting¹, J. E. Clark¹, T. L. Astor², J. Palafox², C. Rogers Marks¹, G. Waldman¹
¹Pharmacy, Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA
*Purpose: Post-transplant complications related to calcineurin inhibitors (CNI) maintenance immunosuppression (MI) may require interim alternative therapies. The goal of this study is to evaluate the…
2021 American Transplant Congress
Accounting for Survivor Bias in Transplant Benefit Models
E. M. Schnellinger¹, E. Cantu², M. O. Harhay¹, D. E. Schaubel¹, S. E. Kimmel¹, A. J. Stephens-Shields¹
¹Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Department of Surgery, Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: The lung allocation system in the U.S. prioritizes lung transplant candidates based on estimated pre- and post-transplant survival. However, these models do not account…
2021 American Transplant Congress
Pregnancy Outcomes in 39 Lung Transplant Recipients
S. Constantinescu¹, L. A. Coscia², A. Yusuf², S. Rao³, M. J. Moritz⁴
¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Transplant Pregnancy Registry International, Philadelphia, PA, ³University of Virginia Heath System, Charlottesville, VA, ⁴Lehigh Valley Health Network, Allentown, PA
*Purpose: The purpose of this study is to describe 52 pregnancies in 39 lung transplant recipients reporting to the Transplant Pregnancy Registry International (TPRI) from…
2021 American Transplant Congress
Prevalence of Hepatitis E Virus Infection in Solid Organ Transplant Recipients: A Systematic Review and Meta-analysis
P. Hansrivijit¹, A. Trongtorsak², B. Boonpheng³, C. Thongprayoon⁴, W. Cheungpasitporn⁴
¹Department of Internal Medicine, UPMC Pinnacle, Harrisburg, PA, ²Department of Internal Medicine, Amita Health Saint Francis Hospital, Evanston, IL, ³Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA, ⁴Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN
*Purpose: Hepatitis E virus (HEV) infection is an underdiagnosed disease due to the use of serological assays with low sensitivity. Although most patients with HEV…
2021 American Transplant Congress
Therapeutic Enoxaparin Dosing in Lung Transplant Recipients
S. Finder, M. Morrison, K. B. Harrison, S. A. Heeney
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Enoxaparin 1 mg/kg subcutaneously every 12 hours for therapeutic anticoagulation is known to increase rates of supratherapeutic anti-Xa levels in lung transplant recipients (LTRs).…
2021 American Transplant Congress
Guiding Therapeutic Plasma Exchange for Amr Treatment in Lung Transplant Recipients Using Serial Dilution in Single Antigen Bead Assay
O. A. Timofeeva¹, J. Choe², M. Alsammak², E. J. Yoon², S. Geier², K. Carney², J. Au², A. Diamond², J. A. Galli², K. Shenoy², A. Mamary², S. Seghal², P. Mullhal², Y. Toyoda², N. Shigemura², F. Cordova², G. Criner², J. Brown²
¹MedStar Georgetown University Hospital, Washington, DC, ²Temple University Hospital, Philadelphia, PA
*Purpose: Development of donor‐specific antibodies (DSA) is associated with poor outcomes in lung transplantation. Patients who are presented with at least probable AMR require treatment;…
2021 American Transplant Congress
Proxies of Ischemia Time Do Not Predict 1-Year Posttransplant Survival
M. Skeans¹, A. Wey¹, E. Lease², C. Lehr³, J. Alcorn⁴, R. Goff⁴, D. Stewart⁴, M. Valapour³
¹SRTR, Minneapolis, MN, ²Univ of Washington, Seattle, WA, ³Cleveland Clinic, Cleveland, OH, ⁴UNOS, Richmond, VA
*Purpose: A barrier to broader distribution of donor organs is a concern that increased donor-to-recipient (DtR) distances could increase ischemia times and compromise posttransplant (PT)…
2021 American Transplant Congress
Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Data from the US Scientific Registry of Transplant Recipients (SRTR)
W. Fitzsimmons¹, J. Erdman², J. Wolfram³, D. Nimke², R. Croy², X. Wang², T. Weaver⁴, D. Schladt⁴
¹University of Illinois at Chicago, College of Pharmacy, Vernon Hills, IL, ²Astellas Pharma, Inc, Northbrook, IL, ³Astellas Pharma Europe BV, Leiden, Netherlands, ⁴Chronic Disease Research Group, Minneapolis, MN
*Purpose: There is currently no FDA approved immunosuppressive regimen for lung transplant (Tx) recipients; however, patients routinely receive a calcineurin inhibitor-based regimen. The SRTR database…

« Previous Page
1
…
7
8
9
10
11
…
42
Next Page »